Zobrazeno 1 - 10
of 163
pro vyhledávání: '"Michael D Jain"'
Autor:
Marion Subklewe, Veit Bücklein, Cecilia Carpio, Frederick L Locke, Andreas Mackensen, Dimitrios Mougiakakos, Michael von Bergwelt-Baildon, Pere Barba, Wolfgang Bethge, Kai Rejeski, Ariel Perez, Gloria Iacoboni, Olaf Penack, Liv Jentzsch, Grace Johnson, Brian Arciola, Viktoria Blumenberg, Eva Hoster, Lars Bullinger, Michael D Jain
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 5 (2022)
Externí odkaz:
https://doaj.org/article/400a6f8385c04652b2cf390c6b50b0b8
Autor:
Pierre Sesques, Amy A. Kirkwood, Mi Kwon, Kai Rejeski, Michael D. Jain, Roberta Di Blasi, Gabriel Brisou, François-Xavier Gros, Fabien le Bras, Pierre Bories, Sylvain Choquet, Marie-Thérèse Rubio, Gloria Iacoboni, Maeve O’Reilly, René-Olivier Casasnovas, Jacques-Olivier Bay, Mohamad Mohty, Magalie Joris, Julie Abraham, Cristina Castilla Llorente, Mickael Loschi, Sylvain Carras, Adrien Chauchet, Laurianne Drieu La Rochelle, Olivier Hermine, Stéphanie Guidez, Pascale Cony-Makhoul, Patrick Fogarty, Steven Le Gouill, Franck Morschhauser, Thomas Gastinne, Guillaume Cartron, Marion Subklewe, Frederick L. Locke, Robin Sanderson, Pere Barba, Roch Houot, Emmanuel Bachy
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-10 (2024)
Abstract Autologous anti-CD19 chimeric antigen receptor (CAR) T cells are now used in routine practice for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Severe (grade ≥ 3) cytokine release syndrome (CRS) and immune effector cell-associate
Externí odkaz:
https://doaj.org/article/8b4e23a2ec6b43d29b08dcb92f281971
Autor:
Kai Rejeski, Doris K. Hansen, Radhika Bansal, Pierre Sesques, Sikander Ailawadhi, Jennifer M. Logue, Eva Bräunlein, David M. Cordas dos Santos, Ciara L. Freeman, Melissa Alsina, Sebastian Theurich, Yucai Wang, Angela M. Krackhardt, Frederick L. Locke, Emmanuel Bachy, Michael D. Jain, Yi Lin, Marion Subklewe
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-13 (2023)
Abstract Background BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side effects that can lengthen hospital stays and increase morbidity. Hematologi
Externí odkaz:
https://doaj.org/article/781664a000bf43b0842a034c8f0fd087
Autor:
Dae Hyun Lee, Sanjay Chandrasekhar, Michael D. Jain, Rahul Mhaskar, Kayla Reid, Sae Bom Lee, Salvatore Corallo, Melanie J. Hidalgo-Vargas, Abhishek Kumar, Julio Chavez, Bijal Shah, Aleksandr Lazaryan, Farhad Khimani, Taiga Nishihori, Christina Bachmeier, Rawan Faramand, Michael G. Fradley, Daniel Jeong, Guilherme H. Oliveira, Frederick L. Locke, Marco L Davila, Mohammed Alomar
Publikováno v:
Cardio-Oncology, Vol 9, Iss 1, Pp 1-9 (2023)
Abstract Background Chimeric antigen receptor T- Cell (CAR-T) immunotherapy has been a breakthrough treatment for various hematological malignancies. However, cardiotoxicities such as new-onset heart failure, arrhythmia, acute coronary syndrome and c
Externí odkaz:
https://doaj.org/article/2b3320c84568447e825867b260a94475
Autor:
Veit Bücklein, Ariel Perez, Kai Rejeski, Gloria Iacoboni, Vindi Jurinovic, Udo Holtick, Olaf Penack, Soraya Kharboutli, Viktoria Blumenberg, Josephine Ackermann, Lisa Frölich, Grace Johnson, Kedar Patel, Brian Arciola, Rahul Mhaskar, Anthony Wood, Christian Schmidt, Omar Albanyan, Philipp Gödel, Eva Hoster, Lars Bullinger, Andreas Mackensen, Frederick Locke, Michael von Bergwelt, Pere Barba, Marion Subklewe, Michael D. Jain
Publikováno v:
HemaSphere, Vol 7, Iss 8, p e907 (2023)
Real-world evidence suggests a trend toward inferior survival of patients receiving CD19 chimeric antigen receptor (CAR) T-cell therapy in Europe (EU) and with tisagenlecleucel. The underlying logistic, patient- and disease-related reasons for these
Externí odkaz:
https://doaj.org/article/96c7942628c54f0395c416764e463604
Autor:
Semira Sheikh, Sepideh Mokhtari, Jeffrey A. Silverman, Kayla Reid, Rawan Faramand, Marco L. Davila, Norman Franke, Frederick L. Locke, Michael D. Jain, Daniel Wong, John G. Kuruvilla
Publikováno v:
eJHaem, Vol 3, Iss 1, Pp 223-227 (2022)
Externí odkaz:
https://doaj.org/article/13b8610a64c74b59a0dc98940dbbade2
Autor:
Michael D. Jain, Jay Y. Spiegel
Publikováno v:
eJHaem, Vol 3, Iss S1, Pp 46-53 (2022)
Abstract Chimeric antigen receptor (CAR) T cell therapy is now approved for the standard of care treatment of several types of relapsed or refractory hematologic malignancies. Future advances may extend cellular therapies to solid tumors or even non
Externí odkaz:
https://doaj.org/article/481ef2690c094004b453b9f5f78bd024
Autor:
Jung W. Choi, Erin A. Dean, Hong Lu, Zachary Thompson, Jin Qi, Gabe Krivenko, Michael D. Jain, Frederick L. Locke, Yoganand Balagurunathan
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
The Metabolic Tumor Volume (MTV) and Tumor Lesion Glycolysis (TLG) has been shown to be independent prognostic predictors for clinical outcome in Diffuse Large B-cell Lymphoma (DLBCL). However, definitions of these measurements have not been standard
Externí odkaz:
https://doaj.org/article/cb6b780ea3d44c4880f11cf1d9fbe271
Autor:
Aasha I. Hoogland, Reena V. Jayani, Aaron Collier, Nathaly Irizarry‐Arroyo, Yvelise Rodriguez, Michael D. Jain, Margaret Booth‐Jones, Kelly A. Hyland, Brian W. James, Anna Barata, Christina A. Bachmeier, Julio C. Chavez, Farhad Khimani, Gabriel S. Krivenko, Aleksandr Lazaryan, Hien D. Liu, Taiga Nishihori, Javier Pinilla‐Ibarz, Bijal D. Shah, Muneer Abidi, Frederick L. Locke, Heather S. L. Jim
Publikováno v:
Cancer Medicine, Vol 10, Iss 6, Pp 1936-1943 (2021)
Abstract Chimeric antigen receptor T‐cell therapy with axicabtagene ciloleucel (axi‐cel) has considerably improved survival in adults with relapsed/refractory large B‐cell lymphoma. This study reports patient‐reported outcomes (PROs) such as
Externí odkaz:
https://doaj.org/article/4e712b76e8e5405caf6b6c0634f8f50e
Autor:
Yucai Wang, Preetesh Jain, Frederick L. Locke, Matthew J. Maurer, Matthew J. Frank, Javier L. Munoz, Saurabh Dahiya, Amer M. Beitinjaneh, Miriam T. Jacobs, Joseph P. Mcguirk, Julie M. Vose, Andre Goy, Charalambos Andreadis, Brian T. Hill, Kathleen A. Dorritie, Olalekan O. Oluwole, Abhinav Deol, Jonas Paludo, Bijal Shah, Trent Wang, Rahul Banerjee, David B. Miklos, Aaron P. Rapoport, Lazaros Lekakis, Armin Ghobadi, Sattva S. Neelapu, Yi Lin, Michael L. Wang, Michael D. Jain
Publikováno v:
Journal of Clinical Oncology. 41:2594-2606
PURPOSE Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell lymphoma (MCL). This therapy was approved on the basis of the single-arm phase II
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1ebedb9cdef4e30b7e8b0e20978feb3
https://doi.org/10.1200/jco.22.01797
https://doi.org/10.1200/jco.22.01797